| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.23676 |
| P698 | PubMed publication ID | 23280794 |
| P50 | author | Massimo Filippi | Q48131182 |
| P2093 | author name string | Diego Cadavid | |
| Daniel Pelletier | |||
| Achim Gass | |||
| Tarek A Yousry | |||
| Ernst-Wilhelm Radue | |||
| Nancy D Richert | |||
| P433 | issue | 5 | |
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 779-787 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy | |
| P478 | volume | 72 |
| Q36242324 | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study |
| Q33806027 | An unusual case of miliary PML-IRIS in an HIV+ patient |
| Q52659119 | Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. |
| Q38116451 | Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards |
| Q52150367 | Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. |
| Q33810020 | Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study |
| Q38152451 | Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? |
| Q90185084 | CNS Infections in Immunoincompetent Patients : Neuroradiological and Clinical Features |
| Q36352813 | Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression. |
| Q92473906 | Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain |
| Q40039520 | Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies |
| Q42226607 | Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? |
| Q41126166 | Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients |
| Q33428818 | Eculizumab-related progressive multifocal leukoencephalopathy |
| Q33573208 | Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis |
| Q48386105 | Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients |
| Q48273360 | Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse? |
| Q38375704 | FLAIRfusion Processing with Contrast Inversion : Improving Detection and Reading Time of New Cerebral MS Lesions |
| Q36887160 | Fingolimod-associated PML in a patient with prior immunosuppression |
| Q55278001 | Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study. |
| Q40342277 | High b-value diffusion-weighted imaging in progressive multifocal leukoencephalopathy in HIV patients. |
| Q35590449 | Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy |
| Q37256223 | Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome |
| Q39247449 | Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis. |
| Q50079049 | Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects |
| Q34818048 | Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab |
| Q41455235 | Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions |
| Q28552120 | JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection |
| Q35586120 | JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis |
| Q39391443 | Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis |
| Q49606221 | MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective |
| Q41361912 | MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. |
| Q40619670 | MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance |
| Q41745436 | MRI pattern in asymptomatic natalizumab-associated PML. |
| Q38172961 | Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system |
| Q37313729 | Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome |
| Q34522015 | Multiple sclerosis imaging: recent advances |
| Q39211049 | Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. |
| Q41386664 | Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. |
| Q38558344 | Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology |
| Q38167347 | Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango |
| Q38786252 | Natalizumab in relapsing-remitting multiple sclerosis |
| Q36568666 | Natalizumab therapy for multiple sclerosis |
| Q35093103 | Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring |
| Q28555138 | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry |
| Q37403424 | Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features |
| Q38221343 | Natalizumab: risk stratification of individual patients with multiple sclerosis |
| Q26781389 | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities |
| Q28082309 | Neurological immune reconstitution inflammatory response: riding the tide of immune recovery |
| Q34562841 | Outcome and survival of asymptomatic PML in natalizumab-treated MS patients |
| Q30613846 | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section |
| Q52587612 | Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. |
| Q48208073 | Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy |
| Q37475542 | Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod |
| Q91830971 | Progressive Multifocal Leukoencephalopathy: Current Insights |
| Q52718488 | Progressive multifocal leukoencephalopathy after fingolimod treatment. |
| Q38577593 | Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). |
| Q102220458 | Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease |
| Q38153637 | Progressive multifocal leukoencephalopathy in multiple sclerosis |
| Q28083338 | Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate |
| Q43897444 | Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? |
| Q58007550 | REPLY: |
| Q30278095 | Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis |
| Q53442107 | Spinal cord progressive multifocal leukoencephalopathy detected premortem by MRI. |
| Q26780412 | Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group |
| Q52665025 | The current role of MRI in differentiating multiple sclerosis from its imaging mimics. |
| Q38115572 | The human JC polyomavirus (JCPyV): virological background and clinical implications |
| Q50102128 | The national incidence of PML in Sweden, 1988-2013. |
| Q33879159 | The use of natalizumab for multiple sclerosis |
| Q47812653 | To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. |
| Q34330211 | Treating multiple sclerosis with monoclonal antibodies: a 2013 update |
| Q90288758 | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration |
| Q34368638 | Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy |
| Q48846624 | Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem |
| Q38616689 | Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update |
| Q31114633 | Use of natalizumab in multiple sclerosis: current perspectives |
| Q59356319 | [MRI alterations in immunomodulation] |
| Q88533703 | [Progressive multifocal leukoencephalopathy] |
Search more.